NCT04332432 is a Phase 1 clinical trial of belapectin in Hepatic Impairment, sponsored by Galectin Therapeutics Inc..

Who is sponsoring NCT04332432?

NCT04332432 is sponsored by Galectin Therapeutics Inc..

What drugs are being tested in NCT04332432?

Interventions in NCT04332432: belapectin.

What condition does NCT04332432 study?

NCT04332432 studies Hepatic Impairment.

Is NCT04332432 still recruiting?

NCT04332432 is currently completed. Last updated 28 March 2022.

Last reviewed 2022-03-28 · How we verify

NCT04332432

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Single-dose, Open-label, Pharmacokinetic Study of Belapectin (GR-MD-02) in Subjects With Normal Hepatic Function and Subjects With Varying Degrees of Hepatic Impairment

Completed Phase 1 Last updated 28 March 2022

What this trial tests

Phase 1 trial testing belapectin in Hepatic Impairment in 38 participants. Completed in 9 March 2022.

Timeline

16 June 2020

Primary endpoint
9 March 2022

9 March 2022

Quick facts

Lead sponsor	Galectin Therapeutics Inc.
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	38
Start date	16 June 2020
Primary completion	9 March 2022
Estimated completion	9 March 2022
Sites	4 locations across United States

Drugs / interventions tested

belapectin — full drug profile →

Conditions studied

Hepatic Impairment — all drugs for Hepatic Impairment →

Sponsor

Galectin Therapeutics Inc. — full company profile →

Who can join

Adults 18 to 75, any sex, with Hepatic Impairment. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study will assess the pharmacokinetics of belapectin in subjects with mild, moderate, or severe hepatic impairment according to 3 different Child-Pugh categories: mild, moderate, or severe impairment, compared to matched healthy control subjects.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Inhibition of galectins in cancer: Biological challenges for their clinical application.
Laderach DJ, Compagno D. · · 2022 · cited 26× · PMID 36703969 · DOI 10.3389/fimmu.2022.1104625
Galectins in the Pathogenesis of Common Retinal Disease.
Caridi B, Doncheva D, Sivaprasad S, Turowski P. · · 2021 · cited 6× · PMID 34079467 · DOI 10.3389/fphar.2021.687495
Glycobiology-driven therapeutic targeting of glycan-binding proteins: mechanisms, diseases, and clinical translation.
Popatia AM, Sharanek A, Jahani-Asl A. · · 2026 · PMID 42248861 · DOI 10.1038/s41392-026-02768-4

Verify or expand the search:

Other trials of belapectin

Trials testing the same drug.

NCT04365868 — Study Evaluating the Efficacy and Safety of Belapectin for the Prevention of Esophageal Varices in NASH Cirrhosis · Phase 2, PHASE3 · terminated

Other recruiting trials for Hepatic Impairment

Currently open trials in the same condition.

NCT07269301 — A Study to Learn How the Body Processes the Study Medicine PF-07328948 in People With and Without Reduced Liver Function · Phase 1 · recruiting
NCT07219550 — A Study of Calderasib (MK-1084) in Participants With Hepatic Impairment and Healthy Volunteers (MK-1084-017) · Phase 1 · recruiting
NCT07144111 — A Study to Evaluate the Effect of Moderate or Severe Hepatic Impairment on the Pharmacokinetics (PK) of Inavolisib · Phase 1 · recruiting
NCT07023354 — A Study to Test How BI 1291583 is Taken up in the Blood of People With and Without Liver Problems · Phase 1 · recruiting
NCT06985615 — A Study of HDM1002 in Subjects With And Without Varying Degrees Of Hepatic Impairement · Phase 1 · recruiting

Other Galectin Therapeutics Inc. trials

Trials by the same sponsor.

NCT04365868 — Study Evaluating the Efficacy and Safety of Belapectin for the Prevention of Esophageal Varices in NASH Cirrhosis · Phase 2, PHASE3 · terminated

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04332432 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Galectin Therapeutics Inc.
Last refreshed: 28 March 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04332432.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing